https://www.selleckchem.com/pr....oducts/protac-tubuli
n of where the panel agreed or disagreed with national guidelines is included. The panel has provided recommendations for managing mCRPC with regard to specific issues (a) biomarker monitoring and the role of genetic and molecular testing; (b) rationale, current strategies, and optimal sequencing of the various approved therapies, including hormonal therapy, cytotoxic chemotherapy, radiopharmaceuticals and immunotherapy; (c) adverse event management and monitoring; and (d) imaging advanced PC patients. These recommenda
Like
Comment
Share
